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Human papillomavirus (HPV) testing might identify older women who could be withdrawn from the cervical screening programme,
or require less frequent screening. A case–control study using the United Kingdom cervical screening population was set up to help
address this issue. Cases comprised 575 women who developed cervical intraepithelial neoplasia (CIN) grade 2 or worse over a 13-
year period following a cytologically normal baseline smear, and were stratified by age group (‘under 20’, ‘20–39’ and 40 years or
over). Controls (n¼601) were women who remained disease free over this interval and were the same age on average as cases.
DNA was extracted from the baseline smears and tested for HPV by PCR using GP5þ/6þ consensus primers. HPVþ samples
were tested for HPV types 16 and 18 using specific PCR primers. In all, 27.0% of cases tested positive for HPV at baseline, compared
with 15.4% of controls (odds ratio (OR)¼2.00; 95% confidence interval (CI), 1.50–2.68). Among women aged 40 years or over, the
OR for HPV 16 was 8.95 (95% CI, 2.63–30.4). These results support the need for further cervical screening of HPV  older women,
as many of the cases were HPV  at baseline.
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Human papillomavirus (HPV) infection has been found to be
present in 99.7% of cervical cancers, and is thus acknowledged as a
necessary cause of this disease (Walboomers et al, 1999). High-risk
viral types have been found to have odds ratios (ORs) in excess of
150 for cervical cancer when HPV status was ascertained at the
time of cancer diagnosis (Munoz et al, 2003). To establish the
extent to which a test for HPV can predict future cervical cancer or
high-grade cervical intraepithelial neoplasia (CIN), either pro-
spective (Koutsky et al, 1992; Schlecht et al, 2003) or nested case–
control studies are needed (Liaw et al, 1999; Wallin et al, 1999;
Ylitalo et al, 2000; van der Graaf et al, 2002).
In case–control studies where archived cervical smears have
been used to detect past infection with genital HPV types, HPV
infection has been found to be associated with both subsequent
invasive cervical cancer and carcinoma in situ (Wallin et al, 1999;
Ylitalo et al, 2000). Equivalent data both for a United Kingdom
population and among older women are required as it has been
suggested that some HPV  older women could be safely
withdrawn from the cervical screening programme in the UK
before the current cessation age of 65 years (Sherlaw-Johnson et al,
1999).
The aim of the present work was to examine the association
between HPV and subsequent cervical disease through a case–
control study, where the case group consisted of a large number of
UK women who developed CIN grade 2 or worse after a
cytologically normal baseline smear. A substantial number of
these were aged 40 years or over at baseline.
MATERIALS AND METHODS
Selection of cases
Cases were identified using cytology and histology records from
the Nottingham cervical cytology centre. Our primary interest was
women aged 40 years or over who had a cytologically normal
screening smear taken between May 1988 and November 1992
(termed the baseline smear) and who subsequently received a
histologically confirmed diagnosis of CIN grades 2 or 3 or cervical
cancer up until September 2002. In the UK, cervical smears have to
be retained for 10 years for legal reasons, meaning that cervical
smears taken after 1992 could not be retrieved for HPV testing. In
total, 204 cases aged 40 years or over at baseline were identified as
eligible and had baseline smears that could be retrieved. Women
aged under 40 years at baseline were also recruited to increase the
overall sample size of the study and to test the hypothesis that the
relationship between the HPV measures and outcome was
modified by age (although prestudy sample size calculations were
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ynot based on this hypothesis; hence, we acknowledge that these
interaction tests may have lacked statistical power). The younger
cases were selected consecutively on the basis of the date of their
baseline smear beginning from May 1988 until around the end of
1988, in order to achieve a sample size of 100 cases aged under 20
years and 275 cases aged 20–39 years. For all age groups, the
earliest smear was chosen when more than one was available
(between May 1988 and November 1992) from each woman in the
study, so as to maximise the length of follow-up available. Any
women who had an abnormal cervical smear of mild severity or
worse prior to the baseline smear were excluded from the list of
possible cases. If a smear of ‘borderline’ severity was recorded
prior to baseline, the woman would be eligible if this was followed
by two cytologically normal smears (including the baseline smear).
Selection of controls
Controls for this study were frequency matched by 10-year age
band (under 20, 20–29, 30–39, 40–49, 50–59, 60 years or over)
and year of baseline smear, in a ratio to cases of 1:1. The eligibility
criteria for the control group were a normal baseline smear and no
subsequent development of abnormal cytology (mild severity or
worse) or diagnosis of CIN 2/3 or invasive cancer up until
September 2002 (the time at which the case group was selected).
Women with a smear recorded as having borderline dyskaryosis
during follow-up were eligible as controls if this was followed by
two normal smears. Selection as a control was not conditional on
having a complete history of normal smears over the subsequent
10–13 years, as the purpose was to select a group of women
representative of all women who did not develop cervical disease
over this time period. However, all controls were required to have
had a minimum of one follow-up smear in order to limit the
potential for the control group to have contained women who
received a diagnosis of CIN 2 or worse outside of the Nottingham
area. Exclusion criteria for controls on the basis of smear
abnormalities prior to baseline were identical to those for cases.
Controls were selected at random from all those eligible,
ensuring that the number of cases and controls were equal within
each age band and for each year of baseline smear. At the time of
slide retrieval, replacement of damaged or missing smears was
carried out for controls by randomly selecting a smear from
another woman on the list of eligible controls. There was a slight
imbalance in the number of cases and controls aged 40 years or
over (n¼224 controls vs n¼204 cases) due to the fact that
replacement smears were available for controls but not for cases.
Anonymisation and ethical considerations
The Nottingham City Hospital Ethics Committee agreed that
women selected for this study would not be contacted in order to
provide consent. This was decided in the context of the 1999
‘Consensus Statement of Recommended Policies for Uses of
Human Tissue in Research Education and Quality Control’ (Royal
College of Pathologists, 1999). When cytology slides were retrieved,
identifiers were erased and replaced with a unique study number.
The study was anonymised so that only investigators based at the
cytology centre (PV, JJ) had access to full clinical data on the study
participants; these investigators did not have access to HPV testing
results at an individual level. Laboratory personnel had no
information on the study participants other than the above study
number, and were blinded to case–control status.
HPV testing
Cytology slides were immersed in xylene (40ml) for 2–3 days to
remove coverslips. Cells were then scraped into an Eppendorf tube
containing ethanol (1ml) using a sterile scalpel blade and
centrifuged to remove any traces of xylene. DNA was extracted
using Qiagent extraction kits (Qiagen, 2004a).
b-globin PCR was carried out for 354 samples (a mixture of
cases and controls) in order to test the integrity of the DNA
extraction process, of which 342 samples (96.6%) tested positive.
Owing to the high percentage of women with b-globinþ smears
and the need to preserve the DNA sample, it was decided that no
further b-globin PCR’s would be performed.
HPV DNA was amplified using real-time PCR (Stratagene
Mx4000) (Seth et al, 2004). The GP5þ and GP6þ consensus
primer pair located in the L1 region of the HPV genome was used
here. These primers amplify a broad spectrum of genital HPV
types in a single reaction (including presently unsequenced HPV
types); hence, infections with both high- and low-risk HPV types
were detected (de Roda Husman et al, 1995). The PCR master mix
(Quantitect, purchased from Qiagen, 2004b) contained optimised
amounts of SYBR
s Green dye to which primers (5pmoltube
 1)
and DNA template (5ml) were added. Standard tubes of HPV 16
DNA (0.01–10pgtube
 1) and blank tubes (no DNA) were included
in all assays. In all, 40 amplification cycles were performed.
Samples that were HPVþ using the GP5þ/6þ primer sequence
were also tested for HPV 16 and HPV 18 using type-specific PCR
primers located within the E7 gene.
Statistical analysis
Odds ratios and 95% confidence intervals (CIs) were calculated
using logistic regression analysis adjusted for age at baseline. Age
was fitted as a linear term for these analyses, although results were
similar when models were rerun with age as a categorical variable.
Subgroup analyses were carried out for age group (under 20,
20–39 and 40 years or over), and with the case group stratified by
both grade of diagnosis (CIN 2, CIN 3 or cervical cancer including
microinvasive squamous cell carcinoma (SCC)) and time in years
between baseline and diagnosis (o4, 4–8 and 48 years).
Exposure measures were infection with any genital HPV type
(based on results from the GP5þ/6þ assay) and infection with
HPV types 16 and 18 specifically.
RESULTS
Characteristics of sample
A total of 1176 women were selected for this study (575 cases and
601 controls). Four cases were excluded when a review of the
biopsy report found that the outcome lesion did not conform to a
grading of CIN 2 or worse. There were insufficient cells for DNA
extraction for 17 smears (seven cases and 10 controls); hence, these
women were excluded. This left a final sample size of 564 cases and
591 controls. The numbers of cases and controls by age group are
shown in Table 1. Of the cases, 167 (29.6%) women had a diagnosis
of CIN 2, 346 (61.3%) had a diagnosis of CIN 3 and 51 (9.0%) had
developed cervical cancer (20 with adenocarcinoma, 16 with SCC,
nine with microinvasive SCC and six with adenocarcinoma in situ).
Among cases, the median length of time between the baseline
Table 1 No. of cases and controls by age at baseline smear
Baseline age (years) Cases (total) CIN 2 CIN 3 Cancer Controls
Under 20 97 30 63 4 100
20–39 267 80 173 14 269
40 or over 200 57 110 33 222
Total 564 167 346 51 591
CIN¼cervical intraepithelial neoplasia.
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ysmear and diagnosis of outcome was 6.8 years (range¼0.1–13.5
years) and the median age at diagnosis was 36.2 years (range 19.1–
76.1 years). Of the four cancer cases who were under age 20 years
at baseline, all developed the outcome 9 or more years after the
time of their baseline smear (minimum age at diagnosis¼27
years). Exclusion of four cases where the time between baseline
and diagnosis was less than 6 months had little impact on results
presented below.
Overall HPV rates
A comparison of the rates of infection with any genital HPV type
(high or low risk) between cases and controls both for the entire
sample and among specific age groups is provided in Table 2.
Cases had significantly higher rates of HPV infection in their
baseline smears than controls (27.0 vs 15.4%). Overall, HPVþ
women had a two-fold increase in the risk of developing an
outcome lesion. The OR was highest for women aged 40 years or
older at baseline, while for the smaller group of women under age
20 years, the difference in HPV status between cases and controls
was not statistically significant. A test for interaction to compare
the magnitude of the ORs across the three age groups (with age
group fitted as a linear term) failed to reach statistical significance
(P¼0.15).
Stratification by grade and time
Cases were stratified according to grade of outcome (or worse
outcome for cases who had more than one abnormal biopsy during
the follow-up period) and the length of time between the baseline
smear and diagnosis; these results are presented in Table 3. The
risk of a more severe grade of outcome lesion increased with
baseline HPV infection, with a significant trend across the case
Table 2 No. (%) of cases and controls positive for any genital HPV type
by age at baseline, along with results from logistic regression analysis
Cases Controls
HPV+ HPV+
Age group (years) (baseline) N (%) N (%) OR
a (95% CI)
Under 20 24 (24.7) 18 (18.0) 1.62 (0.80–3.28)
20–39 79 (29.6) 50 (18.6) 1.82 (1.21–2.72)
40 or over 49 (24.5) 23 (10.4) 2.79 (1.63–4.79)
All ages 152 (27.0) 91 (15.4) 2.00 (1.50–2.68)
HPV¼human papillomavirus; OR¼odds ratio; CI¼confidence interval.
aAdjusted
for age in years using logistic regression.
Table 3 ORs
a showing the effect of HPV positivity at baseline, with cases stratified jointly by grade of diagnosis and time to diagnosis
Time to diagnosis
X8 years (n¼209) 4–8 years (n¼205) o4 years (n¼150) All cases (n¼564) Linear trend
b
Grade of diagnosis
CIN 2 (n¼167) 0.93 (0.44–1.99) 1.56 (0.81–3.03) 2.30 (1.23–4.31) 1.55 (1.01–2.38) P¼0.022
(9/55) (13/57) (16/55) (38/167)
CIN 3 (n¼346) 1.55 (0.97–2.47) 1.90 (1.21–2.98) 3.82 (2.30–6.33) 2.13 (1.54–2.95) Po0.001
(31/132) (35/133) (32/81) (98/346)
Cancer (n¼51) 2.83 (1.11–7.23) 5.65 (1.95–16.3) 1.38 (0.28–6.81) 3.32 (1.71–6.48) Po0.001
(7/22) (7/15) (2/14) (16/51)
All cases (n¼564) 1.47 (0.99–2.20) 1.97 (1.34–2.89) 2.97 (1.96–4.50) — Po0.001
(47/209) (55/205) (50/150)
Linear trend
c P¼0.029 Po0.001 Po0.001 Po0.001
OR¼odds ratio; HPV¼human papillomavirus; CIN¼cervical intraepithelial neoplasia. Numbers in cells represent the OR for the case group compared with controls (and 95%
CI), the numbers within parentheses underneath are the number of HPV+ women/total number of women in case group.
aAll ORs are adjusted for age using logistic regression.
bThe linear trend was calculated by fitting time to diagnosis as the outcome variable in an ordinal logistic regression model (with controls comprising the baseline group).
cThe
linear trend was calculated by fitting grade of lesion as the outcome variable in an ordinal logistic regression model (with controls comprising the baseline group).
Table 4 No. (%) of cases and controls positive for HPV 16 and HPV 18 along with results from logistic regression analysis
Cases
HPV+
Controls
HPV+
OR
a (95% CI)
Age group at baseline N (%) N (%) Model 1
b Model 2
c
HPV 16
Under 20 9 (9.3) 5 (5.0) 2.25 (0.71–7.13) 2.10 (0.61–7.30)
20–39 39 (14.6) 10 (3.8) 4.62 (2.24–9.51) 4.15 (1.99–8.64)
40 or over 22 (11.0) 3 (1.4) 8.95 (2.63–30.4) 9.08 (2.65–31.1)
All ages 70 (12.4) 18 (3.1) 4.48 (2.61–7.55) 4.18 (2.44–7.18)
HPV 18
Under 20 3 (3.1) 3 (3.0) 1.12 (0.22–5.78) 0.85 (0.15–4.95)
20–39 12 (4.6) 6 (2.3) 2.02 (0.74–5.49) 2.15 (0.72–6.44)
40 or over 12 (6.0) 8 (3.6) 1.69 (0.68–4.23) 1.30 (0.49–3.48)
All ages 27 (4.8) 17 (2.9) 1.72 (0.93–3.20) 1.48 (0.77–2.86)
HPV¼human papillomavirus; OR¼odds ratio; CI¼confidence interval.
aFor cases vs controls (logistic regression).
bAdjusted for age in years.
cAdjusted for age in years, infection
with other specific HPV type (16 or 18) and infection with unknown HPV type (positive using GP5+/6+ primers but negative for HPV 16/18).
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ygroups. This trend was most obvious among women aged 20–39
years, among whom eight out of 14 (57.1%) women with cancer
tested positive for HPV at baseline (data not shown). The rate of
baseline HPV positivity was also highest for cases diagnosed
within 4 years of the negative baseline smear, again with a
significant linear trend. When these two stratification variables
were considered jointly, the OR was highest for cancer cases
diagnosed between 4 and 8 years after the baseline smear, although
because of the overlapping confidence intervals no definite
conclusions can be made about the relative effect sizes for the
nine case groups (Table 3).
Rates of HPV 16 and 18
A total of 70 cases and 18 controls tested positive for HPV 16 and
27 cases and 17 controls were positive for HPV 18. These results
are described in more detail in Table 4. Odds ratios were higher for
exposure to HPV 16 compared with exposure to any HPV type
within all three age categories (comparison with results in Table 2).
The association remains nonsignificant, however, for the under 20
years age group. An interaction term fitted to compare the ORs by
age group (with age group fitted as a linear term) failed to reach
statistical significance (P¼0.086). HPV 18 does not have a
significant effect upon the odds of being a case, despite raised
ORs for all three age groups. The interaction between age group
and HPV 18 was also nonsignificant (P¼0.77). When additional
models were fitted to control for infection with the other high-risk
HPV type (16 or 18) and for other HPV types (positive using
GP5þ/6þ primers but negative for HPV 16/18), the ORs
remained significant for HPV 16 and nonsignificant for HPV 18.
The interaction term with age group remained of borderline
significance for HPV 16 (P¼0.066) and nonsignificant for HPV 18
(P¼0.67) when the other HPV terms were adjusted for. When
analyses were performed separately for the three grades of cases
with results combined over age groups and adjusted for the other
HPV types, the effect of HPV 16 was significant among all case
groups (data not shown). For HPV 18, there was a higher OR
among cancer cases, although this was not statistically significant
(OR¼2.99; 95% confidence interval (CI), 0.94–9.49; P¼0.063).
DISCUSSION
This study found that HPV significantly predicts the development
of high-grade cervical disease an average of 6.8 years later. The
magnitude of the ORs varied according to age at baseline smear,
grade of outcome, time to development of outcome and HPV type.
For women aged 40 years or over, infection with HPV 16 was
associated with an approximate 10-fold increase in risk of CIN 2 or
worse. Despite this, however, 73% of cases were HPV  at baseline.
Strengths of the study include the large number of cases, the long
period of follow-up and relevance of the study sample to a
population where HPV testing could be introduced in practice
(older women based in the United Kingdom).
Several aspects of the study design merit attention. First,
controls were not individually matched to cases, instead it was
ensured that numbers of cases and controls were equal within
categories defined by age (10 year bands) and year of baseline
smear. At the time of inception of this study, there was some
concern that many archival cervical smears would contain
insufficient DNA for HPV analysis (as indicated by results from
the b-globin assay). The conditional logistic regression method of
analysis needed for matched case–control data requires data to be
nonmissing for both case and control(s); hence, a large number of
missing values for the exposure variable would make such an
analysis highly inappropriate. All logistic regression analyses
presented here were adjusted for age to allow for the fact that
within each age band, the age distribution of cases was not always
uniform, whereas it was for controls. Second, the selection criteria
for our control group was for women to have had just one
subsequent normal cervical smear, as opposed to a complete
history of normal smears over the 10–13 year follow-up period.
We cannot therefore be sure that all controls remained disease free
over this period, as they may have migrated and presented with
CIN outside of Nottingham. Among a retrospective cohort of
women aged 40 years or over participating in the Nottingham
screening programme, less than 1 woman per 1000 was diagnosed
with CIN (grades 2 or 3) or cancer each year (unpublished data).
This would therefore have had a negligible impact on our results,
although we acknowledge the possibility that such misclassifica-
tion could have been greater for the younger age groups, among
whom the incidence of CIN is higher.
Data are available to suggest that among women who develop
cervical cancer, the high rate of false cytological negativity among
previous cervical smears is an issue (Walboomers et al, 1995). In
this study, smears from cases and controls were not reviewed to
confirm that they were cytologically normal. It can be argued that
as the primary intention of this study was to estimate the impact of
HPV testing within a screening programme, the inclusion of false
negatives among the baseline smears would reflect clinical
practice, and hence their exclusion would be unadvisable (Wood-
man and Collins, 2002). Furthermore, in a previous case–control
study of cervical cancer, the percentage of cases who were HPVþ
at baseline was very similar among women whose smears were
reclassified as abnormal (69%) compared with those whose smears
remained normal (70%); therefore, the impact on results of
excluding the former group would be negligible (Zielinski et al,
2001).
Prospective and nested case–control studies of HPV and
subsequent CIN/cancer have reported ORs of differing sizes
(Woodman and Collins, 2002). Factors that are likely to affect
the size of an observed OR include, among others, the average
length of time between the baseline smear and diagnosis of
outcome and the HPV types tested for (all genital types or high risk
types only). Studies where results have been stratified by the
former have reported higher ORs when the time to diagnosis is
shorter (Wallin et al, 1999; Ylitalo et al, 2000). This may be
consistent with our finding of higher ORs among women aged 40
years or over, among whom the incidence of new HPV infections
after baseline is likely to be lower. Our overall OR (obtained using
the GP5þ/6þ primer sequences) was lower than for many other
studies (Wallin et al, 1999; Carozzi et al, 2000; van der Graaf et al,
2002), which must in part be due to the fact that the PCR primers
used here detected a combination of high- and low-risk HPV types.
Data from other follow-up studies have shown that high-risk HPV
types are associated with a higher risk of subsequent CIN/cancer
than low-risk types (Liaw et al, 1999; Kjaer et al, 2002; van der
Graaf et al, 2002). Our OR for the high-risk type HPV 16 was
similar to that found in a Swedish study, which also used archived
cervical smears (ORs ranged from 5 to 7 depending on age at
baseline), where HPV 16 exposure was assessed in smears taken an
average of 7.8 years before diagnosis (Ylitalo et al, 2000). It was
also consistent with a study of women aged 50 years or over from
the United Kingdom screening population, where the OR for HPV
type 16 was 10.3, where the outcome was a subsequent abnormal
smear over a 10-year follow-up period (Cruickshank et al, 2002).
Two other studies, however, have reported ORs for HPV type 16,
which were noticeably higher than those observed here (Liaw et al,
1999; van der Graaf et al, 2002).
Another possible explanation for the lower ORs observed here,
both for overall HPV and specifically for HPV 16, is the fact that
long-stored archival material was used in the laboratory analysis.
Other studies that have used archival cervical smears have
reported both differing ORs and differences in the percentage of
the case group who were positive for HPV at baseline (Wallin et al,
1999; Carozzi et al, 2000; Ylitalo et al, 2000; van der Graaf et al,
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many instances, this could result in the possibility of false-negative
HPV results, which if occurring equally for case and control
subjects would bias the observed ORs towards unity. This would
not, however, provide an explanation for the relatively high rate of
HPV positivity observed among control women (10% in controls
aged 40 years or over). A difference in the sensitivity of the HPV
test favouring controls would be counterintuitive, on the basis that
replication of the HPV virus should be higher in women who
subsequently go on to develop cervical disease (cases). The
alternative explanation is that crosscontamination of DNA samples
resulted in increased rates of HPV positivity among controls. This
could potentially occur either at the time of smear collection at GP
practices, at the screening laboratory during the process of fixation
and staining, or in the HPV testing laboratory. While set
procedures in our laboratory were followed to ensure that no
contamination occurred at the stage of HPV testing, contamination
at the time of sample collection or preparation has been recognised
as a potential problem when studying archived material (Chua and
Hjerpe, 1995). Such crosscontamination of DNA samples affecting
cases and controls in equal measure would have the effect of
lowering observed ORs. Although there is evidence that archival
smears are a reliable resource for detecting past HPV infection
(Jacobs et al, 2000), there is a shortage of data where HPV results
from the same woman (including typing) are compared between
fresh and long-stored archived cervical smears. Overall therefore,
further research is still needed to determine the impact of using
long-stored specimens for epidemiological purposes such as those
described here.
The causal relationship between HPV and subsequent CIN/
cancer is now well established, but this alone does not provide
sufficient evidence for the introduction of HPV testing in the
cervical screening of older women. In our study, over 70% of cases
tested negative for HPV at baseline. This percentage was higher
among women where the time between baseline and diagnosis was
more than 8 years, but was still 67% among those who developed
CIN/cancer within 4 years of baseline; however, for cases aged 40
years or over, 75% were HPV  at baseline. In a case–control from
Sweden where invasive cancer was the outcome and the average
age at baseline was 44 years, just four out of 35 women (11.4%)
who developed cancer more than 6 years after baseline were
positive for HPV using a consensus PCR method (MY09/11)
(Wallin et al, 1999). These results taken in conjunction would not
support the withdrawal of HPV  older women from cervical
screening, but need to be interpreted in light of the fact that use of
stored (archived) specimens may have resulted in an under-
estimation of HPV infection rates at baseline due to inadequate
DNA preservation. In the United Kingdom, it has been suggested
that cessation of screening for low-risk older women should take
place at age 50 (Flannelly et al, 2004). A direct estimate of the
negative predictive value of an HPV test at or shortly after the age
of 50 years can only be obtained from a large cohort study where
fresh HPV samples are obtained from participants at study entry.
Such data may be required before it can be ascertained for certain
whether or not HPV  women could be safely withdrawn from
cervical screening in the UK.
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